Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
2.
Drug Alcohol Depend ; 204: 107588, 2019 11 01.
Article in English | MEDLINE | ID: mdl-31590131

ABSTRACT

BACKGROUND: The aim was to estimate the prevalence of harmful alcohol use in relation to socio-demographic characteristics among acutely ill medical patients, and examine identification measures of alcohol use, including the alcohol biomarker phosphatidylethanol 16:0/18:1 (PEth). METHODS: A cross-sectional study, lasting one year at one hospital in Oslo, Norway and one in Moscow, Russia recruiting acute medically ill patients (≥ 18 years), able to give informed consent. Self-reported data on socio-demographics, mental distress (Symptom Check List-5), alcohol use (Alcohol Use Disorder Identification Test-4 (AUDIT-4) and alcohol consumption past 24 h were collected. PEth and alcohol concentration were measured in whole blood. RESULTS: Of 5883 participating patients, 19.2% in Moscow and 21.1% in Oslo were harmful alcohol users, measured by AUDIT-4, while the prevalence of PEth-positive patients was lower: 11.4% in Oslo, 14.3% in Moscow. Men in Moscow were more likely to be harmful users by AUDIT-4 and PEth compared to men in Oslo, except of those being ≥ 71 years. Women in Oslo were more likely to be harmful users compared to those in Moscow by AUDIT-4, but not by PEth for those aged < 61 years. CONCLUSIONS: The prevalence of harmful alcohol use was high at both study sites. The prevalence of harmful alcohol use was lower when assessed by PEth compared to AUDIT-4. Thus, self-reporting was the most sensitive measure in revealing harmful alcohol use among all groups except for women in Moscow. Hence, screening and identification with objective biomarkers and self-reporting might be a method for early intervention.


Subject(s)
Alcoholism/blood , Alcoholism/epidemiology , Glycerophospholipids/blood , Hospitalization/trends , Adolescent , Adult , Aged , Alcohol Drinking/blood , Alcohol Drinking/epidemiology , Alcoholism/diagnosis , Biomarkers/blood , Cross-Sectional Studies , Early Intervention, Educational/methods , Female , Humans , Male , Middle Aged , Moscow/epidemiology , Norway/epidemiology , Self Report , Young Adult
3.
Prilozi ; 32(2): 143-55, 2011.
Article in English | MEDLINE | ID: mdl-22286619

ABSTRACT

UNLABELLED: Cefixime is an oral third generation cephalosporin, frequently used in respiratory tract infections (RTI) in the pediatric population. However, in some publications cefixime has demonstrated poor efficacy against staphylococci and streptococci. THE AIM: of this study was to evaluate the efficacy of cefixime in the treatment of community-acquired infections in a country where parenteral third generation cephalosporins have been used for a long time. The present study was designed to assess the clinical efficacy, bacteriological eradication rates and tolerability of cefixime in children with community-acquired upper RTI (URTI), lower RTI (LRTI) and uncomplicated urinary tract infections (UTI). MATERIALS AND METHODS: The study was prospective, open, and included 89 patients, from 6 months to 28 years, of both sexes, with the diagnosis of community-acquired URTI, LRTI and UTI. RESULTS: The treatment with cefixime was successful in 30/30 (100%) patients suffering from acute otitis media (AOM), in 10/12 (83.3%) with acute sinusitis, in 12/12 patients (100%) with pneumonia, in 31/35 (88.57) with uncomplicated UTI. The antibiotic was well tolerated. In 10 days treatment we recorded one case (1.3%) with acute gastroenteritis and two cases (2.6%) of maculopapular rash. Side-effects were transient and disappeared after finishing therapy in all three of the cases. CONCLUSIONS: Community-acquired infections, such as AOM, LRTI and UTI, caused by susceptible pathogens, can be treated with cefixime, as a good choice for a successful clinical response.


Subject(s)
Cefixime/therapeutic use , Community-Acquired Infections , Respiratory Tract Infections , Urinary Tract Infections , Adolescent , Adult , Anti-Bacterial Agents/therapeutic use , Child , Child, Preschool , Community-Acquired Infections/drug therapy , Community-Acquired Infections/microbiology , Female , Humans , Infant , Kosovo , Male , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/microbiology , Staphylococcus/drug effects , Streptococcus/drug effects , Treatment Outcome , Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL